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KESAN SINDROM METABOLIK DIARUH FRUKTOSA TERHADAP 
HEMODINAMIK DAN FUNGSI EKSKRETORI GINJAL PADA TIKUS 
 
 
ABSTRAK 
 
 
       Kajian ini menyelidek sama ada keresponsifan α1-adrenoseptor pada vaskulatur 
ginjal terubah semasa sindrom metabolik yang disebabkan pemberian fruktosa yang 
tinggi. Tikus Sprague-Dawley jantan dirawat selama 8 minggu dengan 20% fruktosa 
dalam air minuman (F), sementara tikus kawalan diberi minum air paip (C) ad 
libitum. Parameter metabolik, fungsian dan hemodinamik dinilai setiap minggu dan 
pada akhir kajian. Pada set yang lain, tikus F diberikan sama ada carvedilol (FCV) 
atau losartan (FL) pada (10mg/kg/hari po) selama 3 minggu bermula dari minggu 
kelima eksperimen. Kumpulan tikus yang lain diberikan tempol, suatu superoksida 
dismutase mimetik (FT) pada (1 mmol/L) dengan 20% fruktos dalam air minuman 
selama 8 minggu. Pada akhir tempoh rawatan, suatu ujian tolerans glukosa insulin 
intervena dijalankan untuk menilai kesensitifan insulin. Selanjutnya, tikus dibius 
dengan pentobarbiton dan pengurangan aliran darah kortikal renal diaruh melalui 
pemberian-secara- intrarenal noradrenalina (NA), fenilefrina (PE), metoksiamina 
(ME) dan angiotensin II (Ang II) yang ditentukan dalam kehadiran dan 
ketidakhadiran 5-metilurapidil (5-MU), kloroetilklonidina (CEC) atau BMY 7378. 
Data, min±SEM tertakluk pada ANOVA dengan kesignifikanan pada P<0.05. Pada 
akhir minggu kelapan, didapati bahawa F mempunyai paras sistemik yang tinggi bagi 
tekanan darah, glukosa plasma, trigliserida dan insulin, tetapi secara signifikannya 
pecahan natrium dan ekskresi kalium adalah rendah jika dibandingkan dengan C. 
Tikus F menunjukkan pengurangan (P<0.05) respons vaskular renal terhadap NA, 
PE, ME dan Ang II jika dibandingkan dengan C. Respons terhadap Ang II secara 
signifikannya adalah berkurangan atau merosot oleh 5-MU, CEC dan BMY 7378, 
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dan juga selepas rawatan dengan  carvedilol, losartan atau tempol pada tikus F dan C. 
Respons adrenergik semakin berkurangan oleh 5-MU dan ditingkatkan oleh CEC 
atau BMY 7378 pada tikus F. Rawatan dengan tempol atau losartan meningkatkan 
respons konstriktor terhadap NA, PE dan ME dibandingkan dengan F. Data ini    
mencadangkan bahawa pengambilan fruktos tinggi kronik akan mengurangkan 
kesensitifan vaskular terhadap agonis adrenergik dan Ang II. Ia juga menghasilkan 
retensi natrium yang boleh menjelaskan tekanan darah tinggi pada tikus-tikus ini. Di 
samping itu, α1A-adrenoseptor merupakan fungsi subjenis yang boleh 
menyederhanakan respons vasokonstriksi dalam tikus yang diberi fruktosa. Ang II 
memainkan peranan penting dalam mengawal atur hemodinamik renal dan perkaitan 
interaktif yang wujud di antara Ang II dan neurotransmisi adrenergik pada tikus-tikus 
ini. Radikal superoksida memainkan peranan penting dalam mengawal respons 
vascular renal terhadap Ang II dan agonis adrenergik keadaan berintangan insulin. 
Tambahan pula, rawatan dengan carvedilol, losartan dan tempol boleh meningkatkan 
kesensitifan insulin dalam model ini. 
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THE EFFECTS OF FRUCTOSE-INDUCED METABOLIC SYNDROME ON 
RENAL HAEMODYNAMIC AND EXCRETORY FUNCTION IN RAT 
 
 
ABSTRACT 
 
 
       This study investigated whether the α1-adrenoceptor responsiveness of the renal 
vasculature was altered in a metabolic syndrome state due to high-fructose feeding. 
Male Sprague-Dawley rats were fed for 8 weeks with 20% fructose in the drinking 
water (F), while their controls received tap water (C) to drink ad libitum. Metabolic, 
functional and haemodynamic parameters were assessed weekly and at the end of the 
study. In another set of rats, F received either carvedilol (FCV) or losartan (FL) at 
(10mg/kg/day po) for 3 weeks starting from week 5 of the experiment. Another 
group of rats received tempol, a superoxide dismutase mimetic (FT) at (1 mmol/L) 
with 20% fructose in drinking water for 8 weeks. At the end of the treatment period, 
an intravenous insulin glucose tolerance test was performed to assess insulin 
sensitivity. Moreover, rats were pentobarbitone anaesthetized and the reductions in 
renal cortical blood flow induced by intrarenal administration of noradrenaline (NA), 
phenylephrine (PE), methoxamine (ME) and angiotensin II (Ang II) were determined 
in the presence and absence of 5-methylurapidil (5-MU), chloroethylclonidine (CEC) 
or BMY 7378. Data, mean±SEM were subjected to ANOVA with significance at 
P<0.05. At the end of the 8 weeks, F had higher systemic blood pressure, plasma 
glucose, triglycerides and insulin levels but significantly lower absolute and 
fractional sodium and potassium excretion as compared to C. The F rats expressed 
reduced (P<0.05) renal vascular responses to NA, PE, ME and Ang II compared to 
C. The response to Ang II was significantly attenuated by 5-MU, CEC and BMY 
7378, and also following carvedilol, losartan or tempol treatments in the F and C rats. 
The adrenergic responses were blunted by 5-MU and enhanced by CEC or BMY 
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7378 in the F. Tempol or losartan treatment enhanced the constrictor responses to 
NA, PE and ME compared to F. These findings suggest that chronic high-fructose 
intake blunts vascular sensitivity to adrenergic agonists and Ang II. It also produced 
sodium retention which may explain high blood pressure in these rats. In addition, 
α1A-adrenoceptor is the functional subtype that mediates renal vasoconstriction 
response in the fructose-fed rats. Ang II plays an important role in regulating renal 
haemodynamics and an interactive relationship exists between Ang II and adrenergic 
neurotransmission in these rats. Superoxide radicals play crucial role in controlling 
renal vascular responses to Ang II and adrenergic agonists in insulin resistant state. 
Moreover, carvedilol, losartan and tempol treatments improved insulin sensitivity in 
this model. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 
 
 
1.1 The metabolic syndrome 
 
       Recently we have witnessed the appearance of the metabolic syndrome with      
its terrifying impacts on human health worldwide. This epidemic syndrome occurs       
as a result of adapting new life style that is characterized by lack of activity                
and bad eating habits. A group of pathologies including hyperlipidemia, 
hypertriglyceridemia, impaired glucose tolerance, insulin resistance and hypertension 
have been collectively reported to be associated with the metabolic syndrome (also 
known as syndrome X or insulin resistance syndrome) (Reaven, 1988, Wajchenberg 
et al., 1994) (Figure 1.1). The metabolic syndrome has been found in approximately 
20% to 30% of a middle-aged population in highly industrialized countries (Hansen, 
1999). For example, it is suggested to present in about 25 to 50% of the population of 
the United States (Keller and Lemberg, 2003) making the metabolic syndrome one of 
the most common diseases. It has been suggested that there is a relationship between 
the metabolic syndrome manifestations and the risk for developing cardiovascular 
disease, type 2 diabetes mellitus and renal disease (Lorenzo et al., 2003, Lakka et al., 
2002, Malik et al., 2004). Although not all people with the metabolic syndrome 
necessarily have diabetes but it is suggested to be a strong prediabetic condition as 
impaired glucose tolerance can readily be converted to type 2 diabetes mellitus 
(LeRoith et al., 2003). In addition, there is a link between the metabolic syndrome 
and premature morbidity and mortality (Keller and Lemberg, 2003, Songer, 1992). In 
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relation to this, recent clinical studies showed that the metabolic syndrome is 
associated with higher risk of proteinuria and chronic kidney disease (Chen et al., 
2004, Kurella et al., 2005). It is also agreed that insulin resistance is the joint 
etiologic factor in the metabolic syndrome (Reaven, 1988).  
 
 
        
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 
metabolic 
syndrome 
 
 
Figure 1.1: The metabolic syndrome or syndrome X: a cluster of pathologies. 
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       There are two pathophysiological components related to the metabolic 
syndrome: genetic and environmental factors (LeRoith et al., 2003). It has been 
found that there is a strong family history of type 2 diabetes mellitus and 
hypertension in individuals who will develop the metabolic syndrome. 
Environmental influences play an important role in developing the metabolic 
syndrome (Reaven, 2003). These may include sedentary lifestyle, smoking, and 
progressive weight gain which can lead to the metabolic syndrome, however, they 
are associated with a very little genetic influence (LeRoith et al., 2003). In addition, 
one of the elements of the lifestyle component of the metabolic syndrome which is 
controllable is nutrition which has the importance of directly influencing humans’ 
health. The increased availability of food rich in calories and the “Westernization” of 
diets have contributed significantly to the epidemic of metabolic syndrome (Basciano 
et al., 2005). Diets rich in fat or carbohydrate have been linked to the metabolic 
syndrome whereby weight gain, insulin resistance, and hyperlipidemia were detected 
in humans and animals (Hill et al., 1992, Kromhout et al., 1995, Kromhout, 2001). 
 
       In order to allow accurate diagnosis of the metabolic syndrome, a precise 
definition of the metabolic syndrome has been introduced. Since insulin resistance 
was highlighted as the major component of this syndrome, therefore, it has been 
suggested that the presence of insulin resistance is required along with two additional 
parameters for the diagnosis of the metabolic syndrome. For example, the National 
Cholesterol Education Program (NCEP), Adult Treatment Panel (ATP III) adapted a 
standard guideline for the metabolic syndrome to be considered (2001). According to 
this guideline, if three of the five following conditions are present in patients, they 
are diagnosed as having the metabolic syndrome.  
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       These conditions are: 
 
 The blood pressure should be greater than or equal to 140/90 mmHg. 
 The fasting plasma glucose level should be greater than or equal to 6.1 
mmol/L. 
 The fasting plasma triglycerides should be greater than or equal to 175 mg/dl. 
 The high density lipoprotein (HDL) cholesterol should be less than or equal 
to 45 mg/dl. 
 Central obesity, defined as a body mass index (BMI) of 30 kg/m2. 
  
       However, it has the disadvantage of carrying the diagnosis without direct 
measure of insulin resistance (2001). Therefore, the American Association of 
Clinical Endocrinologists (AACE) has adapted another criterion to define the insulin 
resistance syndrome based on the NCEP ATP III guideline. In this definition the 
AACE focused on insulin resistance but excluded central obesity and insulin values 
from the definition (Einhorn et al., 2003). Moreover, other criteria, such as a family 
history of type 2 diabetes, hyperuricemia and polycystic ovary syndrome have also 
been included in this definition. Further to this, definitions have been formulated to 
ease the diagnosis of the metabolic syndrome with the inclusion of abdominal 
obesity due to its relation to insulin resistance such as the definition of International 
Diabetes Federation (IDF) (Alberti et al., 2005) and the definition of the American 
Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) (Grundy 
et al., 2005). However, according to Grundy et al., (2005) it seems currently that the 
updated NCEP ATP III guideline is the definition which is used worldwide with 
minor modifications.  
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1.2 Fructose and the metabolic syndrome  
       In order to study the metabolic syndrome in an animal model where similar 
metabolic profile to human is provided, the fructose-fed rat model has been utilized. 
This model develops insulin-resistance, hyperinsulinemia and hypertriglyceridemia 
in a similar fashion to human metabolic syndrome (Hwang et al., 1989b, Miller et al., 
1999). In addition, it is agreed that a high consumption of diet rich in carbohydrates 
is associated with a higher risk of insulin resistance (Liu and Manson, 2001, Jenkins 
et al., 1981). Accordingly, the use of a fructose-rich diet was for a long time used as 
a successful approach to explore the mechanism of the metabolic syndrome 
development (Rayssiguier et al., 2006). Since then, diets specifically high in fructose 
have been shown to induce a metabolic disturbance in animal models with a 
subsequent increase in weight gain (Kanarek and Orthen-Gambill, 1982, Kasim-
Karakas et al., 1996), hyperlipidemia (Kasim-Karakas et al., 1996), and hypertension 
(Sanchez-Lozada et al., 2008b, Dai and McNeill, 1995). Commercially, fructose is 
used to substitute other sugars like glucose or sucrose as a sweetener for desserts, 
condiments and beverages (Daly et al., 1997). Fructose is a monosaccharide that 
resembles glucose in its chemical formula but differs in its chemical structure and is 
sweeter than glucose. It also exists as a disaccharide sugar known as sucrose which 
composed of one glucose molecule attached to a fructose molecule (Figure 1.2). 
 
       Previous studies have investigated on the relation between long-term ingestion 
of high calorie diet such as diet rich in fat and fructose and the occurrence of diabetes 
in human (Gross et al., 2004). Interestingly, the study showed that there is a 
significant association between type 2 diabetes mellitus and the high intake of high 
fructose corn syrup (HFCS).  
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Figure 1.2: Chemical structures of fructose, glucose and sucrose: Sucrose composed 
of one glucose molecule attached to one fructose molecule through a 1-2 glycoside 
bond. 
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       This syrup is reported to contain up to 90% of fructose (Guzman-Maldonado and 
Paredes-Lopez, 1995) and is used to be a constituent of sweetened soft drinks, baked 
goods, candies, jams, dairy products and carbonated beverages in addition to many 
types of food product (Bray et al., 2004). Most importantly, fructose-sweetened soft 
drinks are now one of the most popular drinks worldwide (Park and Yetley, 1993). 
The increase in HFCS consumption had far exceeded the intake of any other food or 
food group (Gaby, 2005). As reviewed by Basciano et al., (2005), HFCS becomes 
problematic due to the increase in its intake and the fact that these high-calorie 
component when consumed are not actually balanced by lowering calories from the 
rest of the diet and this results in energy imbalance (Wharton and Hampl, 2004). 
Collectively, it is obvious that there is a need for a better evaluation and 
understanding of the hazardous effects of high-calorie rich diet on human life and the 
necessity for the proper ways to exclude them. 
 
      Different modes of fructose administration have been described using different 
amounts of fructose which result in variable features of the metabolic syndrome 
(Table 1.1).  The administration of fructose either as drinking form or as a dietary 
component was reported to induce insulin resistance, hypertension and 
hypertriglyceridemia (Sanchez-Lozada et al., 2007, Abdulla et al., 2010b, 2011c). 
The use of either a 10% or 20% fructose solution in hamsters was reported to 
produce hyperglycemia and hyperinsulinemia (Barros et al., 2007). Moreover, a 5-
week consumption of 10% fructose solution in rat was found to induce hypertension 
and insulin resistance (Xu et al., 2010). However, as the amount of fructose ingested 
increased, the manifestations of the metabolic syndrome will also increase.  
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 Study Mode 
 
Species Amount Length  
of study 
Effect 
 Huang et al., (2006) Drink Mouse 10% 3 weeks  -Hypertension, 
  hyperinsulinemia 
 Sanchez-Lozada et al., 
(2007) 
 Xu et al., (2010) 
 
 Bar-On and Stein, (1968) 
Drink Rat 
 
10% 
 
8 weeks 
 
5 weeks 
 
6-19 days 
 -Hypertension,  
  hypertriglyceridemia 
 -Hypertension,  
  insulin resistance 
 -Hypertriglyceridemia  
 Abdulla et al., (2010b) 
 
 
 Motoyama et al., (2010) 
Drink Rat 
 
20% 
 
8 weeks 
 
 
30 days  
 -Hypertension,  
  hyperglycemia,  
  hyperinsulinemia 
 -Impaired glucose 
  tolerance,  
  dyslipidemia 
 Wong and Johns,  (1999) Drink  60% 2 weeks   Hyperglycemia 
 Barros et al., (2007) Drink Hamster 10%,  
20% 
2, 4 & 6  
months 
  Hyperglycemia,  
  hyperinsulinemia 
 Bar-On and Stein, (1968) Drink guinea 
pig 
10% 6-19  
days 
  Hypertriglyceridemia 
 Feletou et al., (2003)    18 weeks   Hyperglycemia 
      
 Farah et al., (2006) Food Mouse 60% 8 weeks  -Hypertension,  
  impaired glucose  
  tolerance,   
  dyslipidemia 
 Sanchez-Lozada et al., 
(2007) 
Food Rat 60% 
 
8 weeks 
6 weeks 
 -Hypertension,  
  hypertriglyceridemia 
 Gersch et al., (2007) 
 
 Jordan et al., (2003) 
 Hwang et al., (1987) 
 
 
 Wong and Johns, (1999) 
Food Rat 66% 4 weeks 
 
2 weeks 
4 weeks 
 
 
4 weeks 
 -Hyperinsulinemia,  
  hypertriglyceridemia 
 -Hyperinsulinemia 
 -Hypertension,  
  hyperinsulinemia,  
  hypertriglyceridemia  
 -Hyperglycemia 
 Taghibiglou et al., (2000) Food Hamster 60% 2 weeks  -Hyperinsulinemia,  
  hypertriglyceridemia 
 Martinez et al., (1994) Food Dog 60% 20-28  
days 
 -Hypertension,  
  insulin resistance,  
  hyperinsulinemia,  
  hypertriglyceridemia  
 Hallfrisch et al., (1983) 
 
 Reiser et al., (1989) 
Food Human 15% 
 
20% 
5 weeks 
 
 -Hyperinsulinemia,  
  hyperglycemia 
 -Hypertriglyceridemia 
      
Table 1.1: The metabolic effects of variable forms of fructose administration in different 
species with different lengths of the feeding periods.  
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       Therefore, it is suggested that the diet form of fructose is associated with 
increased metabolic disturbance and organ damage compared to drinking form 
(Sanchez-Lozada et al., 2007). Furthermore, Dai and McNeill (1995) have shown 
that hypertension in this model of fructose feeding is concentration and time 
dependent. Therefore, the fructose model can be used as a useful approach for 
exploring various aspects of the metabolic syndrome through manipulation of its 
route of administration, amount ingested and length of feeding which may have 
applicability to the human situation as the metabolic syndrome develops. 
 
 
1.2.1 Fructose metabolism 
       Fructose metabolism has gained recent research attention due to its undesirable 
effects and due to its impact on both glucose and lipid metabolism (Elliott et al., 
2002). As reviewed by Basciano et al., (2005), this sugar is readily absorbed from 
diet and rapidly metabolized by the liver and is considered as a potent regulator of 
glycogen synthesis and liver glucose uptake. Therefore it produces catalytic 
improvements due to facilitation of hepatic glucokinase and glucose uptake, 
however, the positive effects of fructose do not continue with chronic fructose 
utilization (McGuinness and Cherrington, 2003). The higher amount of fructose in 
diet produces glucose and fructose malabsorption due to its lipogenic properties in 
addition to elevation in triglycerides (TG) and cholesterol (Ch) levels compared to 
other carbohydrates (Hallfrisch, 1990). 
 
       Fructose metabolism is shown in Figure 1.3. As previously reported (Elliott et 
al., 2002, Tran et al., 2009b, Basciano et al., 2005), fructose goes through a 
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phosphorylation step in the liver by adenosine triphosphate to fructose 1-phosphate 
in the presence of highly expressed fructose-specific fructokinase enzyme. Then, 
fructose 1-phosphate undergoes splitting by aldolase enzyme into three-carbon 
molecules: glyceraldehyde and dihydroxyacetone phosphate. These specific fructose 
end products can be converted to glyceraldehyde 3-phosphate. Therefore, the 
fructose molecule undergoes metabolism into two triose phosphates that bypass the 
main rate-limiting step in glycolysis which is the formation of fructose 1,6-
bisphosphate from fructose 6-phosphate in the presence of phosphofructokinase. 
 
       On the other hand, hepatic glucose metabolism is limited by the ability to store 
glucose as glycogen. Moreover, it can also be prevented by the inhibition of 
glycolysis and additional glucose utilization resulting from the effects of citrate and 
ATP to limit the action of phosphofructokinase (Elliott et al., 2002). In the liver, 
fructose metabolism through the glycolytic pathway results in products such as 
glucose, lactate, pyruvate and glycogen. It is therefore suggested that this is the 
reason for considering high-fructose intake as a risk factor for cardiovascular 
diseases (CVD) (Abdullah et al., 2009). Fructose-derived intermediates enter the 
pathway downstream of the phosphofructokinase enzyme with a resultant formation 
of triglycerides and glycerol 3-phosphate. It is evident that fructose metabolism is a 
highly lipogenic pathway that results in hepatic accumulation of triglyceride and 
consequently hepatic insulin resistance (Basciano et al., 2005). 
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Figure 1.3: Hepatic fructose metabolism (Redrawn with modification from Tran et al., 
2009b and Basciano et al., 2005). 
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1.2.2 Fructose consumption and energy intake 
       Fructose is a natural sugar which is found in many fruits and honey and it is safe 
when consumed by human from its natural sources in a range of 16-20 g per day. 
However, the daily intake has increased significantly due to added fructose in diet to 
around four to five folds resulting in increased weight gain and energy consumption 
(Basciano et al., 2005). This disturbance in energy intake due to fructose is found to 
be accompanied by alterations in the actions of insulin and leptin (Bray et al., 2004), 
a hormone that produces the sensation of satiety. These two hormones are suggested 
to play a key role in the long-term control of energy homeostasis and body adiposity 
(Havel, 2001, 2002). Therefore, it is suggested that fructose promotes obesity more 
than glucose because it is not associated with thermogenesis (Levine, 1986). 
However, it is also reported that dietary fructose intake does not result in significant 
weight gain in a number of studies in rat (Bezerra et al., 2000, Lingelbach and 
McDonald, 2000, D'Angelo et al., 2005, Iyer and Katovich, 1994) and dog (Martinez 
et al., 1994) and this makes this model a proper approach to investigate the 
correlation between the metabolic syndrome and the development of hypertension 
without interference from other factors like obesity or genetic predispositions. 
 
       In contrast, many other reports have shown that this model is associated with 
weight gain in rodents (Abdulla et al., 2010b, Kanarek and Orthen-Gambill, 1982, 
Kasim-Karakas et al., 1996). The reason for this controversy in result from these 
studies is that fructose was introduced at different ages and therefore had different 
impacts on body weight. In relation to that, the introduction of fructose in diet during 
the adulthood period did not stimulate excessive weight gain compared to childhood 
(Huynh et al., 2008). This suggests that the timing of the fructose consumption 
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affects weight gain differently. Interestingly, the increase in energy expenditure in 
rodents was suggested to be a result of activation of the sympathetic nervous system 
(SNS) (Haynes et al., 1997). Furthermore, fructose was suggested to suppress the 
action of leptin and therefore results in weight gain (Teff et al., 2004). The resistance 
to leptin action is associated with an increase in its fasting plasma level (Lee et al., 
2006, Huang et al., 2004, Mooradian et al., 2000, Scarpace and Zhang, 2007). 
However, leptin resistance has also been reported in rats with unchanged plasma 
leptin levels (Shapiro et al., 2008). These reports therefore illustrate an important 
relationship between energy consumption, appetite control and weight gain in this 
model of the metabolic syndrome. 
 
 
1.2.3 Fructose consumption and insulin resistance 
       Insulin resistance is considered to be the earlier and major feature in the 
development of type 2 diabetes mellitus (McGarry, 2002). In addition, it is also 
associated with other manifestations of the metabolic syndrome like dyslipidemia, 
hypertension, oxidative stress, endothelial dysfunction and cardiovascular disease 
(Chisholm et al., 1997). It is known that insulin resistance is associated with 
compensatory hyperinsulinemia which is reported to be the sum of two mechanisms, 
one is primary hypersecretion and the other is adaptive hypersecretion (LeRoith et 
al., 2003). The adaptive hypersecretion is secondary to insulin resistance because of 
the inadequate stimulation of glucose uptake by insulin in target tissues which 
through a feedback mechanism can stimulate the β-cell of the pancreas to enhance 
the rate of insulin production and release (LeRoith et al., 2003). It has been 
previously shown that the intake of fructose-rich diet produced insulin resistance, a 
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condition whereby insulin is unable to produce its effects to suppress hepatic glucose 
production and stimulate glucose uptake in rodents (Hallfrisch et al., 1979, Zavaroni 
et al., 1980, Higashiura et al., 2000), dogs (Martinez et al., 1994) and also in humans 
(Wei et al., 2007, Beck-Nielsen et al., 1980). After short term exposure, it has been 
found that fructose does not stimulate insulin secretion (Curry, 1989) rather the 
insulin resistance and compensatory hyperinsulinemia was induced after long term 
fructose feeding in experimental animals (Blakely et al., 1981, Thorburn et al., 
1989). Fructose-fed rats have been shown to have impaired whole-body insulin 
sensitivity (Thorburn et al., 1989, Higashiura et al., 2000). Different approaches have 
been utilized to assess in vivo insulin sensitivity. For example, the oral glucose 
tolerance test (OGTT) (Abdulla et al., 2010b, Song et al., 2004a), the intravenous 
glucose tolerance test (IVGTT) (Iyer and Katovich, 1996a), intravenous insulin 
glucose tolerance test (IVIGTT) (Viswanad et al., 2006) and hyperinsulinemic-
euglycemic clamp (Einstein et al., 2008, Gupta et al., 2000). Moreover, insulin 
resistance in this model is usually linked to hypertension (Bhanot and McNeill, 1996, 
Reaven, 1988). It has been suggested that the downregultion of the insulin receptors 
and a lower mRNA level of insulin receptors in skeletal muscles is associated with a 
decreased insulin-stimulated glucose utilization and a reduction in insulin sensitivity 
(Catena et al., 2003a). Litherland et al., (2004) have shown that GLUT5 receptors 
which act as fructose transporters have a possible role in the pathology of the 
metabolic syndrome associated with fructose feeding and insulin resistance due to 
the notion that the activity of these receptors is compromised in diabetic rats. It is 
therefore evident that the insulin resistance associated with hyperinsulinemia is 
considered as the most important manifestation of the metabolic syndrome. In 
relation to this, the metabolic syndrome is known previously as insulin resistance 
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syndrome. This may be due to the association of insulin resistance with other 
features of the metabolic syndrome especially hypertension. However, it may be that 
other features yet to be identified are also involved.     
 
 
1.2.4 Fructose consumption and hypertension 
       The fructose-fed rat model is usually associated with systolic hypertension and 
has been reported in several studies (Sanchez-Lozada et al., 2008b, Hwang et al., 
1987, Dai and McNeill, 1995, Abdullah et al., 2009). Insulin resistance associated 
with hyperinsulinemia may play an important role in the development of 
hypertension possibly due to stimulation of the SNS (Reaven et al., 1996). Therefore, 
various interventions utilized to enhance insulin sensitivity in this model were also 
able to normalize blood pressure (Iyer and Katovich, 1994, Higashiura et al., 2000, 
Navarro-Cid et al., 1995). However, blood pressure lowering agents do not 
necessarily ameliorate glucose intolerance and hyperinsulinemia (Elliott et al., 2002). 
It has been reported that the development of high blood pressure may occur as early 
as one week (Dai and McNeill, 1995), others however have shown increased blood 
pressure within 4 to 8 weeks (Verma et al., 1994, Abdulla et al., 2010b, 2011c, Hsieh 
et al., 2005), but interestingly no differences in blood pressure have also been 
reported (D'Angelo et al., 2005). This variation may be attributed to different diet 
composition used by these studies (Johnson et al., 1993), animal age or strain 
(Kotchen et al., 1997) and the techniques utilized to monitor blood pressure 
(D'Angelo et al., 2005, Ferrari et al., 1990). Therefore, it is suggested based on these 
studies that this effect of fructose is time and concentration dependent. The 
mechanism by which fructose induces the development of hypertension is not fully 
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elucidated, however, several factors have been suggested such as hyperinsulinemia 
(Daly et al., 1997), enhanced activity of SNS (Verma et al., 1999, Farah et al., 2006, 
Rosen et al., 1997) or renin-angiotensin system (RAS) (Tran et al., 2009a, Kobayashi 
et al., 1993, Abdulla et al., 2011c), high circulating level of catecholamines (Tran et 
al., 2009a) and endothelin-1 (ET-1) (Juan et al., 1998, Verma et al., 1997b), high uric 
acid production (Reiser, 1985), sodium and fluid retention (DeFronzo, 1981, Reaven, 
1988) and altered vascular activity (Verma et al., 1996b, Miller et al., 1999, Verma et 
al., 1996a). The proposed effect of hyperinsulinemia on blood pressure has been 
supported by the notion that chronic insulin infusion in rat is associated with elevated 
blood pressure (Brands et al., 1991a, Meehan et al., 1994). Moreover, fructose 
feeding has been associated with impaired vascular relaxation (Takagawa et al., 
2001) and an increased expression of the angiotensin II (Ang II) type 1 receptor in 
adipose tissue (Giacchetti et al., 2000). Albeit many studies have explored the 
mechanisms by which fructose intake is associated with hypertension, there is still 
controversy on whether this model produces a significant increase in blood pressure 
or not. Figure 1.4 elucidates proposed mechanisms that may explain fructose induced 
hypertension.  
 
 
1.2.5 Fructose consumption and lipids 
       In addition to hyperinsulinemia and hypertension, fructose intake has been 
reported to produce hyperlipidemia in rodents (Inoue et al., 1995, Okazaki et al., 
1994, Motoyama et al., 2010). High fructose diet is suggested to upregulate the 
lipogenesis pathway and results in increased triglycerides production (Kok et al., 
1996).  
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Figure 1.4: Proposed mechanisms that may explain hypertension and decreased 
vascular responses to vasoactive compounds in the vascular system of fructose-fed 
rats. SNS, sympathetic nervous system; RAS, renin-angiotensin system.  
                                                 18 
       Therefore, higher circulating level of triglycerides was shown to occur due to 
fructose feeding in rat (Herman et al., 1970, Abdulla et al., 2010b, Sanchez-Lozada 
et al., 2007, Gersch et al., 2007). Interestingly, this effect of fructose is also 
concentration dependent (Elliott et al., 2002). Moreover, it has been shown that the 
high plasma level of triglycerides in fructose-fed rats is causally related to the 
development of hypertension in this model (Si et al., 1999). In relation to that, 
Damiano et al., (1999) reported the development of hypertriglyceridemia and 
hypertension but not hyperinsulinemia after 2 weeks of fructose feeding. The 
mechanism by which fructose feeding induces hyperlipidemia is through its 
metabolic pathway whereby glycerol combines with free fatty acids to form 
triglycerides (Jurgens et al., 2005). On the other hand, increased free fatty acids level 
is suggested to alter glucose metabolism and promote the development of 
hyperinsulinemia and insulin resistance (Abdullah et al., 2009). It has been reported 
that insulin resistance may be a factor in causing dyslipidemia in this model 
(Mykkanen et al., 1994, Garg, 1996, Garg et al., 1988) through compensatory 
hyperinsulinemia, increased very low density lipoprotein (VLDL) secretion from the 
liver, and hypertriglyceridemia (Reaven, 1992). The increase in VLDL production 
from the liver during insulin resistance is suggested to be caused by a direct effect of 
insulin in addition to other effects such as the availability of free fatty acids for 
triglycerides formation (Lewis et al., 1995). Moreover, previous studies have shown 
that visceral fat mass is significantly increased in fructose-fed rats (Abdullah et al., 
2009, Abdulla et al., 2010b). Thus the lipid lowering agents such as statins have been 
shown to improve the cardiovascular outcomes through their ability to improve lipid 
profiles, including the reduction of triglycerides. However, this was considered to be 
their indirect effect (Miller et al., 2004). It is evident from the literature that lipid 
                                                 19 
abnormality in insulin resistance state with hypertriglyceridemia being the most 
common feature. In addition, as suggested previously, altered lipid metabolism plays 
a pivotal role in fructose-induced cardiovascular dysfunction (Hsieh and Huang, 
2001). 
 
 
1.2.6 Fructose consumption and vascular dysfunction 
       Due to the fact that the vasculature is responsible for the transport of essential 
molecules to the tissues, any impairment in its function may result in metabolic 
disturbance (Baron and Clark, 1997, Rattigan et al., 1999). In relation to that, 
impaired vascular responses to endothelium-dependent vasodilators have been 
reported in small vessels from fructose-fed, insulin-resistant rats (Miller et al., 1999, 
Katakam et al., 1999, Erdos et al., 2002). However, it is also reported that high blood 
pressure in this model is brought by the impaired endothelial function caused by 
insulin resistance and hyperinsulinemia (Takagawa et al., 2001). In addition, 
increased sensitivity to vasoconstrictor agents was reported in the metabolic 
syndrome due to vascular dysfunction (Shinozaki et al., 2004). One possible 
mechanism which is responsible for vascular dysfunction is the impairment in the 
vascular smooth muscle KCa channels during insulin resistance (Dimitropoulou et al., 
2002, Miller et al., 1999, Despres et al., 1996). Furthermore, it is suggested that the 
effect of insulin on endothelial nitric oxide synthase enzyme (eNOS) expression and 
nitric oxide (NO) production is impaired during insulin resistance resulting in 
impaired endothelium dependent relaxation (Verma et al., 1997a, Kamata and 
Yamashita, 1999) as illustrated in Figure 1.5. In addition, it has been shown that in 
type 2 diabetic or essential hypertensive patients with insulin resistance, the NO-
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dependent vasodilatory response is impaired (Higashi et al., 1997). This is supported 
by the notion that the lipid lowering agents, statins were able to improve endothelial 
function in the metabolic syndrome through upregulation of nitric oxide synthase 
(NOS) expression, reduction of free radical formation and improving KCa function 
(Hernandez-Perera et al., 1998, Miller et al., 2004). From the above studies it 
becomes evident that endothelial dysfunction in the metabolic syndrome is associated 
with insulin resistance and may be responsible for higher blood pressure in this 
model. 
 
 
1.2.7 Fructose consumption and renal sodium handling 
       Insulin resistance is characterized by a defective insulin-mediated vasodilation 
and this produces abnormal reabsorption of sodium from proximal tubules 
(Stenvinkel et al., 1995). Further to this, it has been suggested that this fructose-
induced change in filtration and reabsorption of sodium is attributed to 
hyperinsulinemia in this model (Song et al., 2004b). In support of this notion, the 
infusion of insulin in animals was associated with impaired sodium excretion (Baum, 
1987) and this was further shown in humans (ter Maaten et al., 1999, DeFronzo et al., 
1975). Hence, sodium retention by renal tubules in hyperinsulinemia is therefore 
suggested as a possible mechanism by which hypertension is developed in this model 
(DeFronzo et al., 1975). Due to insulin resistance, the vasodilator effect of insulin is 
impaired and therefore becomes unable to offset the counterregulatory decrease in 
proximal tubular sodium reabsorption during hyperinsulinemia and thus predispose to 
sodium retention (Stenvinkel et al., 1995). Previous studies have shown the reduction 
in sodium excretion after the long-term consumption of fructose rich diet (Nandhini 
                                                 21 
and Anuradha, 2004, Onuma and Nakanishi, 2004, Abdulla et al., 2011c) but at the 
same time others have reported no change in sodium excretion (Navarro-Cid et al., 
1995, Stepp et al., 2007). The lack of any change in sodium excretion after long-term 
fructose feeding suggests that sodium retention per se may not be the reason of 
hypertension in this model (Iyer and Katovich, 1996b). The urinary sodium excretion 
and the renal interstitial hydrostatic pressure have been reported to be regulated by 
NO system in the kidney (Majid et al., 2001, Kone and Baylis, 1997), therefore, any 
defect in that system may result in salt-sensitive hypertension (Ikenaga et al., 1993, 
Cowley et al., 1995, Barton et al., 2000). Furthermore, eNOS which is suggested to 
play a key role in sodium handling (Plato et al., 2000) has been reported to be 
inhibited in the kidney of fructose-fed and, salt-sensitive fructose-fed hypertensive 
rats (Kamata and Yamashita, 1999, Nishimoto et al., 2002). Therefore, the 
mechanism by which fructose results in sodium reabsorption as well as the 
association between insulin and sodium is not well understood and yet to be 
determined.  
 
 
1.2.8 Fructose consumption and progression of renal disease 
       The metabolic syndrome is reported to be associated with microalbuminuria and 
hyperuricemia which are considered the early markers for renal disease (LeRoith et 
al., 2003). The data available regarding the relationship between fructose-feeding and 
the incidence of chronic kidney disease is varying. For example, it has been reported 
that fructose intake is associated with hyperuricemia (Choi and Curhan, 2008, 
Palanisamy et al., 2008, Choi et al., 2008) and albuminuria (Park and Meyer, 1992, 
Shoham et al., 2008, Palanisamy et al., 2008). Manitius et al., (1995) have shown that 
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fructose feeding for 2 weeks produced hyperplasia of mesangial cells in glomeruli 
and results in hyperfiltration. In addition, high fructose feeding has been reported to 
induce kidney hypertrophy, glomerular hypertension, cortical vasoconstriction and 
arteriolopathy (Sanchez-Lozada et al., 2007). Higher plasma creatinine and 
albuminuria have been reported by Palanisamy et al., (2008) following 60 days of 
fructose feeding in the rat. The authors also showed that it results in kidney 
morphological changes including fatty infiltration and thickening of glomeruli. It is 
suggested that hypertension in this model is an indirect cause of renal injury (Gersch 
et al., 2007). On the other hand, altered body homeostasis due to kidney damage may 
contribute to the development of hypertension. The renal damage associated with 
fructose feeding is suggested to be concentration dependent (Sanchez-Lozada et al., 
2007). Accordingly, the development of altered renal haemodynamics and 
morphological changes depends on the occurrence of damaging features of the 
metabolic syndrome due to fructose feeding and is amount related. Furthermore, 
hyperinsulinemia due to fructose feeding plays an important role in the progression of 
renal disease. In support of that, treatment of fructose-fed rats with troglitazone as 
insulin sensitizer and to correct hyperinsulinemia has reduced the progression of renal 
disease (Yoshida et al., 2001). Roysommuti et al., (2002) have proposed that renal 
impairment characterized by impaired diuresis and natriuresis and higher glomerular 
filtration rate and filtration fraction after long term intake of diet high in 
carbohydrates is dependent on an intact RAS due to the fact that treatment with 
angiotensin converting enzyme (ACE) inhibitor captopril has corrected these 
impairments. On the other hand, it has been reported that the higher urinary NO 
excretion in fructose-fed rats may suggest a role of the renal NO system in the 
pathogenesis of the early renal changes induced by fructose intake (Cosenzi et al., 
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2002b). In the mentioned study, fructose feeding for one month produced glomerular 
hypertrophy and increased expression of inducible nitric oxide synthase enzyme 
(iNOS) isoform in the kidney. The role of NO is evident by the ability of L-NAME, a 
nitric oxide synthase enzyme inhibitor to inhibit these renal changes (Cosenzi et al., 
2002b). Although hyperinsulinemia is suggested to contribute to the pathogenesis of 
renal disease in this model but to date, the exact mechanisms responsible for the 
morphological and functional changes in the kidney of fructose-fed rat have not been 
identified.  
 
 
1.3 Oxidative stress 
1.3.1 What is oxidative stress? 
       Oxidative stress is an imbalance of the prooxidant antioxidant ratio. It is therefore 
the failure of the protective antioxidant mechanism to compensate the rise in free 
radical production. This results in cellular damage which ultimately leads to organ 
death. Oxidative stress plays a role in numerous clinical conditions such as diabetes, 
atherosclerosis, chronic inflammation and ischemia-reperfusion injury (LeRoith et al., 
2003, Griendling and FitzGerald, 2003). As a result of oxidative stress, several 
defense mechanisms can be developed by the biological system. These mechanisms 
may either be preventive, repair, physical and antioxidant in nature. 
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1.3.2 Free radicals 
       Free radicals have been discovered in the biological systems more than 50 years 
ago (Commoner et al., 1954) and is defined as any atom or group of atoms that 
possesses one or more unpaired electron (Aitken et al., 2006). In addition, free 
radicals are either electrically charged or neutral and are unstable and highly reactive. 
Therefore, due to their high activity, free radicals can combine with another atom or 
atoms that have unpaired electrons causing their oxidation. High levels of free 
radicals produce harmful effect to cellular components such as proteins, membrane 
lipids and nucleic acids due to their ability to modify the structure of these 
biomolecules and ultimately result in cell death (Maritim et al., 2003).  
 
 
1.3.3 Reactive oxygen species 
       Reactive oxygen species (ROS) are metabolites which are produced as a result of 
oxygen reduction. Examples of ROS are superoxide anion (O2¯
•
), hydroxyl radical 
(
•
OH), alkoxyl radical (RO
•
), hydrogen peroxide (H2O2) and organic hydroperoxides 
(ROOH). In addition, the term ROS may include strong oxidants such as peroxynitrite 
(ONOO¯) and the most biologically active free radical (
•
NO) (Taniyama and 
Griendling, 2003). Superoxide anion is one of the most important ROS in the 
vasculature (Taniyama and Griendling, 2003) and formed through a one electron 
reduction of O2 (Wolin et al., 2002). It has a role in the regulation of cell 
proliferation, migration, and apoptosis through the formation of H2O2 (Rhee, 1999, 
Taniyama and Griendling, 2003). ROS play an important role in mediating the 
consequences of oxidative stress in the body in addition to promoting the biochemical 
pathways which are necessary for normal cellular function. In addition, ROS exert 
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multiple roles within the cardiovascular system by acting as signaling molecules at 
lower concentrations. Therefore, ROS could have a beneficial effect when they are in 
small quantities but a harmful effect when higher amount is generated (Aitken et al., 
2006). The superoxide anion is considered as a primary ROS and is produced in the 
mitochondria by the one-electron reduction of O2 (Valko et al., 2005). This process is 
reported to be mediated by either enzymatic (NADPH oxidase or xanthine oxidase) or 
nonenzymatic redox-reactive compounds (Droge, 2002) (Figure 1.5). Mitochondria 
are considered an important source of ROS (Andreyev et al., 2005, Raha and 
Robinson, 2000) and most importantly superoxide production. However, the 
formation of ROS contributes to mitochondrial damage in a range of pathologies 
(Droge, 2002). In addition, mitochondrial superoxide dismutase enzyme (MnSOD) 
(Weisiger and Fridovich, 1973) is reported to scavenge superoxide radical by 
converting it into H2O2 (Deby and Goutier, 1990, Fridovich, 1978). This indicates the 
biological significance of mitochondrial superoxide production (Murphy, 2009). The 
H2O2 can be then converted into the highly reactive hydroxyl radical (
•
OH) in the 
presence of reduced transition metals such as ferrous (Fe
2+
) ion (Chance et al., 1979, 
Kehrer, 2000) through the Fenton reaction (Figure 1.5). However, the H2O2 may 
otherwise be converted into water by the enzymes catalase or glutathione peroxidase 
(Droge, 2002). The H2O2 is known to be a stable ROS and an important signaling 
molecule in vascular cells. It has been suggested that the oxidant imbalance during 
oxidative stress is characterized by increased O2¯
• 
and decreased NO availability 
(Zhang et al., 2003). Therefore, it is evident that different ROS coexist in the reactive 
environment each of which may be responsible for a given biological effect. 
 
 
